Clinical trial

A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)

NCT01354990

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Sitagliptin (JANUVIA®) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)

Design: OBSERVATIONAL · Status: COMPLETED · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusCOMPLETED

Study typeOBSERVATIONAL

Start date2009-02-01

PhaseN/A

Conditions

Diabetes Mellitus, Type 2verified · MONDO: type 2 diabetes mellitus

Interventions

Sitagliptin (JANUVIA®)DRUG

Sponsors & collaborators

Merck Sharp & Dohme LLClead sponsor

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT01354990 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.